AI Article Synopsis
- The CHAARTED trial establishes Docetaxel chemotherapy as the standard treatment for metastatic bone prostate cancer.
- A case study of a 70-year-old man receiving treatment showed a significant decrease in PSA levels and improvement in bone lesions via CT scan after six cycles of Docetaxel.
- Despite the positive response indicated by PSA and CT results, bone scintigraphy still showed persistent metastatic lesions, highlighting a gap in timing for evaluation methods.
Article Abstract
Current treatment of metastatic bone prostate cancer with Docetaxel chemotherapy per CHAARTED trial is standard of care. Timing of CT and bone scintigraphy for evaluation of successful treatment of lytic lesions is not available in the literature. We present a case of a 70 year old male with PSA of 586 and wide spread metastatic bone lytic lesions, who underwent androgen deprivation therapy and six cycles of Docetaxel chemotherapy. The patient had clinically successful treatment. Contrast enhanced CT scan demonstrated sclerotic bone lesions with PSA 2.5 at this point in treatment; however, 99mTc-MDP bone scintigraphy remained positive for metastatic lesions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855904 | PMC |
| http://dx.doi.org/10.1016/j.eucr.2015.12.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!